Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Mol Psychiatry. 2018 Jan 9;23(8):1764–1772. doi: 10.1038/mp.2017.249

Figure 4.

Figure 4

Parallel increases in extracellular glutamate and CBV following ketamine and blockade by the mGluR 2/3 agonist and glutamate release inhibitor LY379268. (a) Extracellular glutamate measured with amperometry. (b) Overlay of time courses of ketamine-induced increases of glutamate (black) and CBV (red line). (c) Relative to saline pretreatment (red line), LY379268 pretreatment (purple line) blocks ketamine-induced increases in extracellular glutamate. (d) Similar blockade effect of LY379268 pretreatment in ketamine-induced increase in CBV.

HHS Vulnerability Disclosure